Stockscreener 앱 받기
2.55
8.05%
0.19
시간 외 거래:
2.63
0.08
+3.14%
전일 마감가:
$2.36
열려 있는:
$2.39
하루 거래량:
3.23M
Relative Volume:
1.62
시가총액:
$391.33M
수익:
$38.69M
순이익/손실:
$-108.95M
주가수익비율:
-2.0859
EPS:
-1.2225
순현금흐름:
$-141.09M
1주 성능:
+2.82%
1개월 성능:
-2.67%
6개월 성능:
+7.59%
1년 성능:
+19.16%
1일 변동 폭
$2.39
$2.67
1주일 범위
$2.35
$2.67
52주 변동 폭
$1.66
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
명칭
Editas Medicine Inc
전화
617-401-9000
주소
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.55 | 377.52M | 38.69M | -108.95M | -141.09M | -1.2225 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-28 | 개시 | H.C. Wainwright | Buy |
| 2024-12-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-13 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-11-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-04 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-05-09 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-10-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | 업그레이드 | Stifel | Hold → Buy |
| 2023-06-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-13 | 개시 | Citigroup | Neutral |
| 2022-12-06 | 재개 | Credit Suisse | Neutral |
| 2022-11-18 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-09-29 | 개시 | BofA Securities | Neutral |
| 2021-10-19 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-24 | 개시 | Stifel | Hold |
| 2021-09-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-08-09 | 업그레이드 | Truist | Hold → Buy |
| 2021-08-05 | 업그레이드 | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | 개시 | Goldman | Sell |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-26 | 다운그레이드 | Truist | Buy → Hold |
| 2021-01-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | 개시 | Robert W. Baird | Underperform |
| 2020-06-18 | 재개 | SunTrust | Buy |
| 2020-02-21 | 개시 | Wells Fargo | Equal Weight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-10 | 개시 | Guggenheim | Neutral |
| 2018-09-21 | 개시 | Raymond James | Outperform |
| 2018-05-15 | 재확인 | Chardan Capital Markets | Buy |
| 2018-02-13 | 개시 | CLSA | Underperform |
| 2018-01-23 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-07-14 | 개시 | SunTrust | Hold |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-06-02 | 개시 | Jefferies | Hold |
| 2016-02-29 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-29 | 개시 | JP Morgan | Neutral |
| 2016-02-29 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Editas Medicine Inc - GuruFocus
COMMODORE CAPITAL LP Acquires Significant Stake in Editas Medici - GuruFocus
Editas Medicine CFO Amy Parison sells $1,253 in stock By Investing.com - Investing.com South Africa
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock By Investing.com - Investing.com South Africa
Editas Medicine CEO Gilmore O’Neill sells $41,542 in stock - Investing.com
Editas Medicine CFO Amy Parison sells $1,253 in stock - Investing.com
Editas Medicine (EDIT) CFO logs small automatic tax-related share sale - Stock Titan
Editas Medicine (EDIT) CEO logs automatic, tax-related share sale - Stock Titan
Editas Medicine (EDIT) CSO sells 731 shares under automatic tax-cover plan - Stock Titan
EDIT: EDIT-401 shows durable 90% LDL and Lp(a) reduction, with clinical trials starting in 2024 - TradingView
Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report? - Yahoo Finance
RA Capital affiliates report 8.89M shares in Editas Medicine (EDIT) - Stock Titan
TCG Crossover group reports 9.9% stake in Editas Medicine (EDIT) after offering - Stock Titan
Commodore reports 16.05M-share position in Editas Medicine (EDIT) under 9.99% cap - Stock Titan
Editas Medicine Inc stock (US28106W1036): Q1 2026 loss narrows as Nasdaq-listed gene-editing player - AD HOC NEWS
Genome Editing Market to Reach $13.36 Billion by 2035, Growing - openPR.com
Editas Medicine Q1 2026 Earnings: Narrowing Losses on Reduced Expenses as CRISPR Pipeline AdvancesEBITDA Analysis - newsline.com
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? - The Motley Fool
Editas Medicine Inc stock (US28106W1036): Nasdaq gene-editing share trades quietly ahead of next cat - AD HOC NEWS
EDIT (NASDAQ) insider notice: 15,000-share resale; 32,957 RSUs vested - Stock Titan
Cardiovascular in-licensing play Kardigan looking for quick path to IPO: Finance Report - biocentury.com
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference - Caledonian Record
Editas Medicine: Resetting Pipeline Just To Be Second To Market Again (NASDAQ:EDIT) - Seeking Alpha
Q2 EPS Estimates for Editas Medicine Raised by HC Wainwright - MarketBeat
Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX - RTTNews
Analysts Issue Forecasts for Editas Medicine Q2 Earnings - MarketBeat
Editas Medicine (EDIT) Unveils Promising Data for EDIT-401 - GuruFocus
Editas Medicine (EDIT) Showcases Promising Preclinical Findings - GuruFocus
Evercore Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Editas Medicine stock dips on proposed equity offering - MSN
Editas Medicine Announces $319.4 Million Public Offering with CRISPR Gene Editing Focus - Minichart
HC Wainwright Weighs in on Editas Medicine Q3 Earnings - MarketBeat
Editas Medicine (NASDAQ: EDIT) sells 55.6M shares with warrants to fund EDIT-401 - Stock Titan
Editas Medicine (NASDAQ: EDIT) prices equity deal, extends cash runway to 2H 2028 - Stock Titan
Editas Medicine Prices Public Offering of Shares, Warrants - Moomoo
Editas Medicine Proposes Public Stock Offering; Shares Fall Pre-Bell - Moomoo
H.C. Wainwright Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Editas Medicine (EDIT) Initiates Public Offering of Common Stock - GuruFocus
Editas Medicine (EDIT) Shares Drop Following Stock Offering Anno - GuruFocus
EDIT: Financing Efforts Advance with Recent Offering - GuruFocus
Editas Medicine prices $125M stock offering with warrants - Investing.com UK
Editas Medicine prices $125M stock offering with warrants By Investing.com - Investing.com Nigeria
Editas Medicine stock tumbles on stock offering announcement By Investing.com - Investing.com Australia
Editas reports preclinical data for gene editing treatment - Investing.com UK
Editas Medicine Inc (EDIT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Editas Medicine Inc 주식 (EDIT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| O'Neill Gilmore Neil | CEO |
Jun 03 '26 |
Sale |
2.70 |
15,380 |
41,543 |
248,313 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER |
Jun 03 '26 |
Sale |
2.70 |
731 |
1,975 |
67,297 |
2.60%
0.94%
자본화:
|
볼륨(24시간):